Thursday, August 31, 2017 8:21:44 AM
This will likely bounce back, but don't expect it to be fast.
The best course of action is to repost USRM response or simply the pertinent question list to all social media outlets, and urge citizens to pressure their representatives - both local and national - to address the issue.
If the arguments are upheld, it could mean disaster for existing autologous and homologous transplant therapies already in existence(i.e. skin grafting for burn victims). If there is considerable pressure from the public, then the therapies of USRM can be seen for the non-drug intervention that they are.
Either way, this is not an overnight rocket ride. Expect a snail's pace movement - you know, an act of congress - that hopefully will one day allow this company to thrive.
I am not a huge holder, but I do have a desire to see these therapies made available to patients in need. I have far too many of my own suffering from heart failure, and would welcome the option of a safe and minimally invasive therapy for overall improvement in quality of life for these patients.
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM